Advertisement

BioPortfolio.com — the life science, pharmaceutical and healthcare portal

17:04 EDT 19th June 2013 — BioPortfolio

Breaking News at 17:04 EDT 19th June 2013

Latest BioPortfolio blog: Edison Investment - BioAlliance Pharma - Initiation of coverage - Stand and de-Liva

BioAlliance develops drugs for orphan oncology indications and to treat infections. Most of its products are widely used medicines in new formulations for use in novel indications. Its lead oncology product, Livatag, is in Phase III for liver cancer with... — Read more

Search BioPortfolio: